The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 12.82 billion by 2028, registering a CAGR of 0.5% over the forecast period, according to a new report by the publisher Increased funding for R&D of anti-VEGF therapeutics to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products coupled with the increasing geriatric population that is susceptible to develop ophthalmic diseases is expected to propel the market growth over the forecast period.
According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 68.7 million in Africa, 549.2 million in Asia, 183 million in Europe, 78.4 million in North America, and more than 76 million in Latin America & other regions in 2017. Hence, the increasing geriatric population is anticipated to drive the market.
The lack of reimbursement policies in developing regions is creating an opportunity for cost-effective novel molecules. In addition, ophthalmologists switching to more effective newly launched drugs has compelled companies to invest in R&D to maintain their industry position. The interest of investigators on biosimilar of existing drugs is a major trend in the pipeline of anti-VEGF therapeutics.
Moreover, companies are developing various formulations and drug delivery systems that may increase the adoption of these therapies. For instance, F. Hoffmann La Roche Ltd. is developing the port delivery system-RG6321 (Ranibizumab)-which is currently undergoing a phase III clinical trial. It is an eye implant that is refillable and continuously delivers a customized formulation of ranibizumab over a period of months.
Loss of patent protection is likely to have a negative impact on the market growth and has led big pharma companies to consider new revenue streams. However, this is creating an emerging market for biosimilar drug producers in the space. This rising competition is anticipated to impede market growth. However, the launch of novel products with a competitive advantage is anticipated to lower the impact of the restraint during the forecast period.
According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 68.7 million in Africa, 549.2 million in Asia, 183 million in Europe, 78.4 million in North America, and more than 76 million in Latin America & other regions in 2017. Hence, the increasing geriatric population is anticipated to drive the market.
The lack of reimbursement policies in developing regions is creating an opportunity for cost-effective novel molecules. In addition, ophthalmologists switching to more effective newly launched drugs has compelled companies to invest in R&D to maintain their industry position. The interest of investigators on biosimilar of existing drugs is a major trend in the pipeline of anti-VEGF therapeutics.
Moreover, companies are developing various formulations and drug delivery systems that may increase the adoption of these therapies. For instance, F. Hoffmann La Roche Ltd. is developing the port delivery system-RG6321 (Ranibizumab)-which is currently undergoing a phase III clinical trial. It is an eye implant that is refillable and continuously delivers a customized formulation of ranibizumab over a period of months.
Loss of patent protection is likely to have a negative impact on the market growth and has led big pharma companies to consider new revenue streams. However, this is creating an emerging market for biosimilar drug producers in the space. This rising competition is anticipated to impede market growth. However, the launch of novel products with a competitive advantage is anticipated to lower the impact of the restraint during the forecast period.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Report Highlights
- In 2020, Age-related Macular Degeneration (AMD) accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
- Diabetic retinopathy is anticipated to witness significant growth over the forecast period due to increasing cases of diabetes across the globe
- The Beovu segment is expected to grow at the fastest CAGR over the forecast period due to the geographic expansion and patent exclusivity
- Product expansions in various geographic regions are expected to increase sales and customer base
- North America was the largest regional market in 2020 due to the high disease prevalence, rising consumer awareness, proactive government measures, technological advancements, and improvements in healthcare infrastructure
- Asia Pacific is anticipated to witness the fastest CAGR over the forecast period due to a rise in the penetration of anti-VEGF products, rising disposable income, and growing consumer awareness
Table of Contents
Chapter 1 Methodology and Scope1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
Chapter 3 Anti-VEGF Therapeutics Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Scenario
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.2 Market Restraint Analysis
3.5 Anti-VEGF Therapeutics: Market Analysis Tools
3.5.1 Industry Analysis - Porter’s
3.5.2 Pestel Analysis
3.6 Pipeline Analysis
3.6.1 Pipeline Analysis, By Phase
Chapter 4 Anti-VEGF Therapeutics Market: Segment Analysis, By Disease, 2017 - 2028 (USD Million)
4.1 Anti-VEGF Therapeutics Market: Disease Movement Analysis
4.2 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.3 Macular Edema
4.3.1 Macular Edema Market, 2017 - 2028 (USD Million)
4.4 Diabetic Retinopathy
4.4.1 Diabetic Retinopathy Market, 2017 - 2028 (USD Million)
4.5 Retinal Vein Occlusion
4.5.1 Retinal Vein Occlusion Market, 2017 - 2028 (USD Million)
4.6 Age-related Macular Degeneration
4.6.1 Age-Related Macular Degeneration Market, 2017 - 2028 (USD Million)
Chapter 5 Anti-VEGF Therapeutics Market: Segment Analysis, By Product, 2017 - 2028 (USD Million)
5.1 Anti-VEGF Therapeutics Market: Product Movement Analysis
5.2 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.3 Eylea
5.3.1 Eylea Market Estimates And Forecast, 2017 - 2028 (USD Million)
5.4 Lucentis
5.4.1 Lucentis Market Estimates And Forecast, 2017-2028, (USD Million)
5.5 Beovu
5.5.1 Beovu Market Estimates And Forecast, 2017-2028, (USD Million)
Chapter 6 Anti-VEGF Therapeutics Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)
6.1 Anti-VEGF Therapeutics Market: Regional Movement Analysis
6.2 Regional Market Share Analysis, 2020 & 2028
6.3 Regional Market Snapshot
6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2017 to 2028
6.4.1 North America
6.4.1.1 North America market estimates and forecast, 2017-2028 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 U.S. anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Canada anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.2 Europe
6.4.2.1 Europe anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 U.K. anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Germany anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.2.4 Spain
6.4.2.4.1 Spain anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.2.5 France
6.4.2.5.1 France anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.2.6 Italy
6.4.2.6.1 Italy anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.3.2 Japan
6.4.3.2.1 Japan anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.3.3 China
6.4.3.3.1 China anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.3.4 India
6.4.3.4.1 India anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.3.5 Australia
6.4.3.5.1 Australia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Brazil anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Mexico anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Argentina anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.5 MEA
6.4.5.1 MEA anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 South Africa anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Saudi Arabia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 UAE anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Chapter 7 Anti-VEGF Therapeutics Market: Competitive Analysis
7.1 Recent Developments & Impact Analysis, by Key Market Participants
7.1.1 New Product Launch
7.1.2 Mergers & Acquisitions
7.1.3 Licensing And Partnerships
7.2 Company Categorization
7.2.1 Innovators
7.2.2 Market Leaders
7.2.3 Heat Map Analysis
7.3 Vendor Landscape
7.3.1 List Of Key Distributors And Channel Partners
7.3.2 Key Customers
7.3.3 Key Company Market Share Analysis, 2020
7.4 Public Companies
7.4.1 Company Market Position Analysis
7.4.2 Company Market Position Analysis
7.4.3 Competitive Dashboard Analysis
7.5 Private Companies
7.5.1 List Of Key Emerging Companies
7.6 Company Profiles
7.6.1 F. HOFFMANN-LA ROCHE LTD
7.6.2 BAYER AG
7.6.3 REGENERON PHARMACEUTICALS INC.
7.6.4 NOVARTIS AG
7.6.5 BIOGEN
7.6.6 COHERUS BIOSCIENCES
7.6.7 PFIZER INC.
7.6.8 VIATRIS INC. (MYLAN N.V)
7.6.9 AMGEN INC.List of Tables
Table 1 List of abbreviation
Table 2 North America anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 3 North America anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 4 U.S. anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 5 U.S. anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 6 Canada anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 7 Canada anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 8 Europe anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 9 Europe anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 10 U.K. anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 11 U.K. anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 12 Germany anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 13 Germany anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 14 France anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 15 France anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 16 Italy anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 17 Italy anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 18 Spain anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 19 Spain anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 20 Asia Pacific anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 21 Asia Pacific anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 22 Japan anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 23 Japan anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 24 China anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 25 China anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 26 India anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 27 India anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 28 Australia anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 29 Australia anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 30 Latin America anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 31 Latin America anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 32 Brazil anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 33 Brazil anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 34 Mexico anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 35 Mexico anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 36 Argentina anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 37 Argentina anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 38 MEA anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 39 MEA anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 40 South Africa anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 41 South Africa anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 42 Saudi Arabia anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 43 Saudi Arabia anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
Table 44 UAE anti-VEGF therapeutics market, by product, 2017 - 2028 (USD Million)
Table 45 UAE anti-VEGF therapeutics market, by disease, 2017 - 2028 (USD Million)
List of Figures
Figure. 1 Anti-VEGF therapeutics market segmentation
Figure. 2 Market research process
Figure. 3 Information procurement
Figure. 4 Primary research pattern
Figure. 5 Market research approaches
Figure. 6 Value-chain-based sizing & forecasting
Figure. 7 QFD modeling for market share assessment
Figure. 8 Market formulation & validation
Figure. 9 Market outlook (2020)
Figure. 10 Segment Outlook (Type, 2020)
Figure. 11 Penetration & growth prospect mapping
Figure. 12 Market driver relevance analysis (Current & future impact)
Figure. 13 Geriatric population in 2019 and 2050
Figure. 14 Market restraint relevance analysis (Current & future impact)
Figure. 15 Porter’s five forces analysis
Figure. 16 PESTEL analysis
Figure. 17 Anti-VEGF therapeutics market disease type outlook: Key takeaways
Figure. 18 Anti-VEGF therapeutics market: Disease type movement analysis
Figure. 19 Macular edema market, 2017 - 2028 (USD Million)
Figure. 20 Diabetic retinopathy market, 2017 - 2028 (USD Million)
Figure. 21 Retinal vein occlusion market, 2017 - 2028 (USD Million)
Figure. 22 Age-related macular degeneration market, 2017 - 2028 (USD Million)
Figure. 23 Anti-VEGF therapeutics market product outlook: Key takeaways
Figure. 24 Anti-VEGF therapeutics market: Product movement analysis
Figure. 25 Eylea market, 2017 - 2028 (USD Million)
Figure. 26 Macular edema market, 2017 - 2028 (USD Million)
Figure. 27 Diabetic retinopathy market, 2017 - 2028 (USD Million)
Figure. 28 Retinal vein occlusion market, 2017 - 2028 (USD Million)
Figure. 29 Age-related macular degeneration market, 2017 - 2028 (USD Million)
Figure. 30 Lucentis estimates and forecast, 2017-2028 (USD Million)
Figure. 31 Macular edema market, 2017 - 2028 (USD Million)
Figure. 32 Diabetic retinopathy market, 2017 - 2028 (USD Million)
Figure. 33 Retinal vein occlusion market, 2017 - 2028 (USD Million)
Figure. 34 Age-related macular degeneration market, 2017 - 2028 (USD Million)
Figure. 35 Beovu estimates and forecast, 2017 - 2028 (USD Million)
Figure. 36 Regional outlook, 2020 & 2028
Figure. 37 Regional market place: Key takeaways
Figure. 38 North America
Figure. 39 North America anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 40 U.S.
Figure. 41 U.S. anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 42 Canada
Figure. 43 Canada anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 44 Europe
Figure. 45 Europe anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 46 UK
Figure. 47 UK anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 48 Germany
Figure. 49 Germany anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 50 Spain
Figure. 51 Spain anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 52 France
Figure. 53 France anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 54 Italy
Figure. 55 Italy anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 56 Asia Pacific
Figure. 57 Asia Pacific anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 58 Japan
Figure. 59 Japan anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 60 China
Figure. 61 China anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 62 India
Figure. 63 India anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 64 Australia
Figure. 65 Australia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 66 Latin America
Figure. 67 Latin America anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 68 Brazil
Figure. 69 Brazil anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 70 Mexico
Figure. 71 Mexico anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 72 Argentina
Figure. 73 Argentina anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 74 Middle East and Africa
Figure. 75 MEA anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 76 South Africa
Figure. 77 South Africa anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 78 Saudi Arabia
Figure. 79 Saudi Arabia anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 80 UAE
Figure. 81 UAE anti-VEGF therapeutics market, 2017 - 2028 (USD Million)
Figure. 82 Strategy mapping
Figure. 83 Heat map analysis
Figure. 84 Company market share analysis, 2020
Figure. 85 Company market position analysis
Figure. 86 Company market position analysis
Figure. 87 Market differentiators
Companies Mentioned
- F. HOFFMANN-LA ROCHE LTD
- BAYER AG
- REGENERON PHARMACEUTICALS INC.
- NOVARTIS AG
- BIOGEN
- COHERUS BIOSCIENCES
- PFIZER INC.
- VIATRIS INC. (MYLAN N.V)
- AMGEN INC.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 105 |
| Published | September 2021 |
| Forecast Period | 2020 - 2028 |
| Estimated Market Value ( USD | $ 11.67 Billion |
| Forecasted Market Value ( USD | $ 12.82 Billion |
| Compound Annual Growth Rate | 0.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
